Meeting
2024 ASCO Genitourinary Cancers Symposium
Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).
Authors
Ding-Wei Ye
Fudan University Shanghai Cancer Center, Shanghai, China
Ding-Wei Ye , Jian Zhang , Hua Yang , Jin Yang , Tongsen Zheng , Hongmei Sun , Xuechao Wan , Ge Lan , Guilan Sun , Xiao Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
SYS6002-001
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 622)
DOI
10.1200/JCO.2024.42.4_suppl.622
Abstract #
622
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
First Author: Jonathan E. Rosenberg
Poster
2013 ASCO Annual Meeting
MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC.
First Author: Khaldoun Almhanna
Poster
2024 ASCO Annual Meeting
A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
First Author: Alexander I. Spira
Poster
2023 ASCO Annual Meeting
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).
First Author: Ashish M. Kamat